Tempus AI
About Tempus AI
Tempus AI is a leading health technology company that leverages artificial intelligence (AI) and machine learning to advance precision medicine. Founded in 2015 by Eric Lefkofsky, the company was inspired by the need for more data-driven approaches in oncology care. Tempus has since built one of the world’s largest libraries of multimodal clinical and molecular data, coupled with an operating system (the Tempus Platform) designed to make this vast dataset accessible and actionable for healthcare providers and researchers.
For physicians, Tempus offers “Intelligent Diagnostics” that utilize AI, including generative AI, to enhance the accuracy, tailoring, and personalization of laboratory tests. Their AI-enabled physician platform, Hub, provides secure access to comprehensive patient insights, including guideline-matched therapies, information on treatment resistance, and opportunities for clinical trial enrollment. The platform also features “Patient Similarities” to identify comparable patient cases and “Consults” for secure peer-to-peer collaboration among clinicians. Tempus aims to optimize treatment decisions by matching a patient’s unique molecular profile with targeted therapies and rapidly identifying relevant clinical trials, thereby striving to deliver the right treatment to the right patient at the right time.
Beyond initial diagnostics, Tempus provides an automated “Active Follow-Up” service that delivers updated therapy recommendations as clinical guidelines evolve or new therapeutic options emerge, often without requiring a new patient sample. While initially focused on oncology, the company has expanded its reach to include other critical disease areas such as cardiology, neuropsychiatry (e.g., depression, anxiety, ADHD), infectious diseases, and radiology. Tempus also plays a significant role in drug discovery and development by offering de-identified clinical and molecular data and analytical tools to pharmaceutical and biotech companies, facilitating research and the development of next-generation therapeutics.
Focus Areas
Business Intelligence
| Key Investors | SoftBank Group, Baillie Gifford, New Enterprise Associates (NEA), Novo Holdings, Franklin Templeton Investments, T. Rowe Price, Revolution LLC, Google LLC, Ares Management |
| Partnerships | Gilead Sciences, Blood Cancer United®, Predicta Biosciences, Illumina, Northwestern University's Abrams Research Center on Neurogenomics, ARPA-H, GSK, AstraZeneca, SoftBank (Japan JV - SB Tempus), Mercy, Stemline Therapeutics |
| Acquisitions | Paige (Aug 2025), Deep 6 AI (Mar 2025), Ambry Genetics (Nov 2024), Mpirik (Mar 2023), Highline Sciences (2022), Arterys (2022), AKESOgen (2019) |
| Technology | Tempus Platform (AI operating system), Intelligent Diagnostics, multimodal data library, generative AI, cloud-native, Hub (physician portal), Lens (analytical platform), Next (care pathway intelligence), Algos (algorithmic models), Tempus ONE (AI-enabled assistant) |
| FDA Clearances | 4 cleared products (estimated) |
What the Web Says
Tempus AI is a technology company focused on AI-enabled precision medicine, diagnostics, and data-driven healthcare innovation. While the company is praised for its mission-driven work and innovative use of AI in healthcare, employee reviews often highlight significant concerns regarding management, work-life balance, and compensation. Product reviews suggest that Tempus AI's tools are valuable for aggregating biomarkers and assisting in mutation-guided precision medicine, though some note that their assays have competitors and that AI is sometimes more of a 'punchline' than a core differentiator.
Overall: MixedStrengths
- Mission-driven work with real-world healthcare impact and improving patient outcomes through technology.
- Collaborative environment and smart coworkers.
- Opportunities to work on innovative technology at the intersection of AI and healthcare, including large-scale healthcare datasets and multimodal AI models.
- Strong revenue growth in genomics and data and services.
- Products are easy to use and helpful for tracking time and managing projects (referring to 'Tempus Resource' and 'Tempus' workforce management software).
- Helpful for aggregating biomarkers and research partnerships in oncology.
Limitations
- Poor work-life balance and employees often feel stretched thin.
- Management is frequently criticized for being disorganized, lacking transparency, having poor communication, and exhibiting toxic tendencies.
- Pay is not always market value, and there is negligible upward mobility and tiny salary increases.
- No 401K matching.
- Promotions are sometimes based on tenure rather than merit.
- Some Reddit discussions express skepticism about the company's profitability and the actual implementation of AI beyond a marketing term.
Based on reviews from: Indeed.com, Built In, AIToolsBox, Reddit, GuruFocus, Capterra, G2
Last updated: 2026-07-19
Videos
News, demos, and interviews about Tempus AI.
Videos load interactively. If none appear, search YouTube for Tempus AI →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Tempus AI.
Related Companies
Precision Medical Ventures, Inc. Dba Revealdx (RevealDx) is a Seattle-based healthcare AI company focused on dramatically improving lung cancer outcomes through non-invasive diagnosis. They develop advanced, radiomics and AI-enabled, lung cancer decision support software. Their flagship product, RevealAI-Lung, is a Computer-Assisted Diagnostic (CADx) software that analyzes patient lung computed tomography (CT) images to provide information […]
SafeBeat Rx is a healthcare AI company focused on transforming cardiac care by expanding access to remote patient monitoring (RPM), continuous telemetry, event monitoring, and software-enabled remote therapeutic monitoring (RTM). The company’s core offering is an integrated technology that utilizes automated artificial intelligence-based software to analyze electrocardiogram (ECG) data. This technology is designed to replace […]
Measure Labs, Inc., operating as PreemptiveAI, Inc., is a healthcare AI company focused on transforming healthcare from reactive disease management to proactive risk identification and prevention. The company has developed a “revolutionary” foundation model, a large-scale machine learning model, that interprets biomedical signals from smartphones and wearable devices to predict health outcomes in real-time. This […]
EarliPoint Health, formerly EarliTec Diagnostics, is a healthcare AI company dedicated to transforming autism care through innovative, FDA-cleared eye-tracking technology. The company’s core product, the EarliPoint System, is a medical device designed to aid qualified clinicians in the diagnosis and assessment of Autism Spectrum Disorder (ASD) in children aged 16 months through 95 months (7 […]
Onera B.V., operating as Onera Health, is a Dutch med-tech company that is transforming sleep diagnostics and monitoring with its innovative, self-applied, no-wire polysomnography (PSG) solution. [12, 19] Founded as a spin-off from the imec research center, a leader in nanoelectronics and digital technologies, Onera aims to make clinical-grade sleep studies broadly accessible, convenient, and […]
Digestaid – Artificial Intelligence Development SA is a healthcare AI company focused on developing advanced deep learning solutions for the detection of digestive lesions. The company aims to revolutionize gastrointestinal practice by applying AI technologies across digestive and pancreatobiliary tracts, as well as functional tests. Their solutions are designed to overcome diagnostic limitations of current […]